Surrogate Endpoints: Benefits, Issues And The Future
Executive Summary
On a mild day in April 2016, a Marriott Hotel conference room in Hyattsville, Md., was the scene of one of the most politically charged panel meetings the US Food and Drug Administration held in years. A throng of parents and young boys in wheelchairs hoped to convince a committee to endorse the use of a controversial drug for Duchenne muscular dystrophy, a rare and fatal muscle-wasting disease.
You may also be interested in...
The John Green Effect: Will Industry Be Influenced Again?
Drug and device makers regularly use media to sway consumers. But some advocacy groups recently turned the tables by using social media to sway industry.
Pressure Mounts On Pharma To Act On Environmental Targets
There are growing demands from government officials, investors and employees for the pharmaceutical industry to reduce emissions and waste, and – most of all – make environmental sustainability a core part of its business.
Would You Like Chips With That? High-Tech Alternatives Could Replace Animal Testing
The FDA Modernization Act 2.0 should make it easier for companies to gain regulatory authorization using non-traditional testing methods, like organs-on-a-chip. But biopharma will need to make the leap into technology to help build knowledge and data if the drug development world is to move away from animal testing entirely.